teneligliptin + glinide

Teneligliptin + glinide is a **combination therapy** involving two distinct classes of oral antidiabetic drugs used for the management of type 2 diabetes mellitus. *Teneligliptin* is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (notably GLP-1 and GIP), increasing insulin secretion and suppressing glucagon release in a glucose-dependent manner. *Glinide* refers to short-acting insulin secretagogues (such as repaglinide or nateglinide), which stimulate rapid insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels. When used together, this combination improves glycemic control by targeting both insulin secretion and incretin hormone pathways. This strategy is typically considered for patients with inadequate glycemic control on monotherapy and has shown efficacy and general tolerability in long-term use[1].